Physician
Athens Medical Associates, LLC
Athens Medical Associates, LLC was paid $3.89M by Medicaid between Jan 2018 and Feb 2020, across 100 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 40% of everything it billed.
33Billing provider infoATHENS MEDICAL ASSOCIATES, LLC
ATHENS, OH 45701
ATHENS, OH 45701
33aNPI1982714358assigned 08/30/2006
33bProvider typeInternal Medicine Physician
28Total paid$3.89M
24GClaims122,510
24DCodes billed100
24AFirst – last monthJan 2018 – Feb 2020
Compared with peers
Next to other Internal Medicine Physician providers in Ohio
Rank by total paid#12 of 663
Median peer was paid$17K
This provider vs. median223×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 56,591 | $1.80M | |
| 2019 | 57,178 | $1.78M | |
| 2020 | 8,741 | $302K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 40% | 40,324 | 36,912 | $1.56M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 35% | 26,574 | 24,271 | $1.36M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 3.9% | 9,574 | 3,544 | $150K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.0% | 2,184 | 2,143 | $116K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.5% | 1,925 | 1,877 | $96K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.3% | 1,519 | 1,500 | $90K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.9% | 1,679 | 1,595 | $74K |
| 98929 | <1% | 1,019 | 840 | $33K | |
| 88307 | <1% | 748 | 728 | $31K | |
| 80305 | <1% | 3,958 | 2,935 | $30K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 779 | 763 | $25K |
| 98928 | <1% | 815 | 621 | $23K |
88 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,882 | $22K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 330 | $21K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 378 | $21K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 954 | $19K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 270 | $17K |
| 99220 | <1% | 253 | $12K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 954 | $11K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 172 | $11K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 174 | $11K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 162 | $11K |
| 99460 | <1% | 130 | $10K | |
| 98927 | <1% | 455 | $9K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 694 | $9K |
| 20610 | <1% | 231 | $8K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 220 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,350 | $7K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 450 | $7K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 723 | $6K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 190 | $6K |
| 99217 | <1% | 243 | $5K | |
| 92551 | <1% | 781 | $5K | |
| 90686 | <1% | 450 | $5K | |
| 81025 | <1% | 657 | $4K | |
| 51798 | <1% | 403 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 251 | $3K |
| 82962 | <1% | 1,989 | $3K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 259 | $3K |
| 88304 | <1% | 291 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,400 | $3K |
| 98926 | <1% | 160 | $3K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 328 | $2K |
| 99173 | <1% | 842 | $2K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 28 | $2K |
| 96127 | <1% | 474 | $2K | |
| 45384 | <1% | 13 | $2K | |
| H1000 | Prenatal care, at-risk assessment | <1% | 124 | $2K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 133 | $1K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 145 | $1K |
| 11750 | <1% | 19 | $1K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 80 | $1K |
| 90682 | <1% | 58 | $1K | |
| 76813 | <1% | 13 | $1K | |
| 52000 | <1% | 15 | $1K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 54 | $835.65 |
| 99219 | <1% | 28 | $812.34 | |
| 99462 | <1% | 21 | $742.50 | |
| 99223 | Prolong inpt eval add15 m | <1% | 12 | $736.90 |
| 54150 | <1% | 13 | $664.88 | |
| 88302 | <1% | 84 | $645.61 | |
| 81002 | <1% | 304 | $600.66 | |
| 81003 | <1% | 317 | $495.72 | |
| 99307 | <1% | 163 | $475.71 | |
| 20550 | <1% | 24 | $408.47 | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 13 | $392.34 |
| 11720 | <1% | 89 | $374.49 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 30 | $348.35 |
| 90670 | <1% | 685 | $333.90 | |
| 99251 | <1% | 13 | $322.01 | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 143 | $309.06 |
| 90698 | <1% | 712 | $254.40 | |
| 59025 | Fetal non-stress test | <1% | 12 | $231.44 |
| 90680 | <1% | 280 | $222.60 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15 | $196.12 |
| 90744 | <1% | 151 | $190.80 | |
| 90700 | <1% | 30 | $190.80 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 37 | $156.22 |
| 90685 | <1% | 54 | $143.10 | |
| 90713 | <1% | 14 | $79.50 | |
| 86308 | <1% | 13 | $60.66 | |
| 90633 | <1% | 55 | $31.80 | |
| 36416 | <1% | 22 | $27.07 | |
| 1036F | 0% | 1,193 | $0.00 | |
| 3074F | 0% | 840 | $0.00 | |
| 3079F | 0% | 152 | $0.00 | |
| 3044F | 0% | 81 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 25 | $0.00 |
| 3075F | 0% | 14 | $0.00 | |
| 3080F | 0% | 12 | $0.00 | |
| 90696 | 0% | 14 | $0.00 | |
| 3078F | 0% | 615 | $0.00 | |
| 2028F | 0% | 543 | $0.00 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 2,023 | $0.00 |
| 4004F | 0% | 831 | $0.00 | |
| 3045F | 0% | 303 | $0.00 | |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 2,023 | $0.00 |
| 3046F | 0% | 187 | $0.00 | |
| 3077F | 0% | 28 | $0.00 | |
| 90710 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROTHSTEIN, MARK (EXECUTIVE DIRECTOR)